RVMD

Revolution Medicines Inc

RVMD, USA

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

https://www.revmed.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RVMD
stock
RVMD

HRT Financial LP Increases Position in Revolution Medicines, Inc. $RVMD MarketBeat

Read more →
RVMD
stock
RVMD

Holocene Advisors LP Lowers Holdings in Revolution Medicines, Inc. $RVMD MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$81.15

Analyst Picks

Strong Buy

8

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

9.35

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-19.11 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.55 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.41

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 96.43% of the total shares of Revolution Medicines Inc

1.

Vanguard Group Inc

(8.4317%)

since

2025/06/30

2.

Farallon Capital Management, L.L.C.

(7.6635%)

since

2025/06/30

3.

HHG PLC

(5.6655%)

since

2025/06/30

4.

Wellington Management Company LLP

(5.4885%)

since

2025/06/30

5.

Baker Bros Advisors LP

(5.0098%)

since

2025/06/30

6.

BlackRock Inc

(4.6334%)

since

2025/06/30

7.

FMR Inc

(4.4536%)

since

2025/06/30

8.

Nextech Invest, Ltd.

(4.0662%)

since

2025/06/30

9.

Paradigm Biocapital Advisors LP

(3.2596%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.8228%)

since

2025/07/31

11.

Bvf Inc

(2.6653%)

since

2025/06/30

12.

State Street Corp

(2.5244%)

since

2025/06/30

13.

T. Rowe Price Associates, Inc.

(2.5153%)

since

2025/06/30

14.

T. Rowe Price Investment Management,Inc.

(2.5085%)

since

2025/06/30

15.

Bellevue Group AG

(2.4497%)

since

2025/06/30

16.

BB Biotech AG Ord

(2.34%)

since

2024/12/31

17.

Alphabet Inc

(2.2111%)

since

2025/06/30

18.

Vanguard Small Cap Index

(2.1784%)

since

2025/07/31

19.

Vanguard Health Care Inv

(2.0723%)

since

2025/06/30

20.

Holocene Advisors, LP

(1.9434%)

since

2025/06/30

21.

Deerfield Management Co

(1.8103%)

since

2025/06/30

22.

Fidelity Growth Compy Commingled Pl S

(1.752%)

since

2025/07/31

23.

Geode Capital Management, LLC

(1.6016%)

since

2025/06/30

24.

Woodline Partners LP

(1.5597%)

since

2025/06/30

25.

Casdin Capital, LLC

(1.5449%)

since

2025/06/30

26.

Janus Inst Mid Cap Growth CF

(1.2861%)

since

2025/06/30

27.

Janus Henderson Enterprise D

(1.2861%)

since

2025/06/30

28.

Fidelity Growth Company Fund

(1.2818%)

since

2025/07/31

29.

Vanguard Small Cap Growth Index Inv

(1.2285%)

since

2025/07/31

30.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0061%)

since

2025/07/31

31.

SPDR® S&P Biotech ETF

(0.9988%)

since

2025/08/31

32.

US Small-Cap Growth II Equity Comp

(0.8871%)

since

2025/06/30

33.

T. Rowe Price US Mid-Cap Growth Equity

(0.8024%)

since

2025/06/30

34.

T. Rowe Price Mid-Cap Growth

(0.801%)

since

2025/07/31

35.

T. Rowe Price Health Sciences

(0.7277%)

since

2025/07/31

36.

Vanguard Explorer Inv

(0.662%)

since

2025/06/30

37.

Janus Henderson Global Life Sciences D

(0.6064%)

since

2025/06/30

38.

Janus Henderson Global Life Sciences

(0.6064%)

since

2025/06/30

39.

Janus Henderson Glb Life Scn I2 USD

(0.5625%)

since

2025/07/31

40.

iShares Biotechnology ETF

(0.5167%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.54

Latest Release

Date

2025-09-30

EPS Actual

-1.61

EPS Estimate

-1.41

EPS Difference

-0.2

Surprise Percent

-14.1844%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.